Oral cefaclor for treatment of bronchitis--a comparative double-blind study versus amoxycillin.
Either 500 mg cefaclor or amoxycillin was administered at random thrice daily to 50 adult outpatients with acute or acute-to-chronic bronchitis. A total of 31 pathogens were isolated from sputum, mostly Streptococcus pneumoniae [17] or Haemophilus influenzae [3], or both [2]. All pathogens but one were susceptible to cefaclor; all but six were susceptible to amoxycillin. Satisfactory clinical results were obtained in 62.5% of the patients treated with cefaclor and 66% of the patients treated with amoxycillin.
D000658:Amoxicillin / Q000378:metabolism / Q000627:therapeutic use*; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002433:Cefaclor / Q000378:metabolism / Q000627:therapeutic use*; D002506:Cephalexin / Q000031:analogs & derivatives*; D002908:Chronic Disease; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans
D002433:Cefaclor; D000658:Amoxicillin; D002506:Cephalexin